Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets

Journal of Diabetes

Volumn 9, Issue 1, 2017, Pages 34-44

  Mata Cases, Manel ^a,b,e   Mauricio, Dídac ^a,d,e   Franch Nadal, Josep ^a,c,e  

^a INSTITUT UNIVERSITARI D'INVESTIGACIÓ EN ATENCIÓ PRIMÀRIA JORDI GOL   (Spain)

^b La Mina Primary Health Care Centre   (Spain)

^c INSTITUT CATALÀ DE LA SALUT   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

fasting plasma glucose; glycemic control; insulin treatment; type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; DIET RESTRICTION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; INSULIN; MALE; MIDDLE AGED;

EID: 84959431622     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12373     Document Type: Article

References (62)

1. Mata M, Antoñanzas F, Tafalla M, Sanz P. The cost of type 2 diabetes in Spain: The CODE-2 study. Gac Sanit. 2002; 16: 511–520.
2. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002; 25 (Suppl. 1): S28–S32.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577–1589.
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580–591.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–853.
6. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014; 37 (Suppl. 1): S14–S80.
7. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: Implications for treatment and monitoring of metabolic control. Diabetes Care. 2001; 24: 2023–2029.
8. Franch J, Artola S, Diez J, Mata M. Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud [The RedGEDAPS quality of care program]. The evolution of quality care indicators of patients with type 2 diabetes in the Spanish primary care (1996–2007). Medicina Clínica (Barc). 2010; 135: 600–607[in Spanish].
9. Vinagre I, Mata-Cases M, Hermosilla E, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care. 2012; 35: 774–779.
10. Mata-Cases M, Mauricio D, Vinagre I, et al. Treatment of hyperglycaemia in type 2 diabetic patients in a primary care population database in a Mediterranean area (Catalonia, Spain). J Diabetes Metab. 2014; 5: 338.
11. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281: 2005–2012.
12. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011; 34: 2508–2514.
13. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough: What next? Diabetes Metab Res Rev. 2007; 23: 257–264.
14. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007; 77: 280–285.
15. Peter R, Dunseath G, Luzio SD, Chudleigh R, Choudhury SR, Owens DR. Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes. Diabet Med. 2009; 26: 974–980.
16. Heller S Reducing hypoglycaemia with insulin analogues. Int J Obes. 2002; 26(Suppl. 3): S31–S36.
17. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: Implications of recent clinical trials. Ann Intern Med. 2011; 154: 554–559.
18. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S, Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996–2003. Diabet Med. 2005; 22: 1420–1426.
19. Sicilia CD. Five-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics. Diabetes Care. 2008; 31: 57–62.
20. Morris AD, Boyle DI, MacAlpine R, et al. The Diabetes Audit and Research in Tayside Scotland (DARTS) study: Electronic record linkage to create a diabetes register. BMJ. 1997; 315: 524–528.
21. Sperl-Hillen JM, O'Connor PJ. Factors driving diabetes care improvement in a large medical group: Ten years of progress. Am J Manag Care. 2005; 11(Suppl.): S177–S185.
22. Institut Català de Salut. Institut Català de Salut: Info corporativa. Available at: http://www.gencat.cat/ics/infocorp/assitencia.htm, accessed 2 January 2016.
23. Bolíbar B, Fina F, Morros R, et al. SIDIAP database: Electronic clinical records in primary care as a source of information for epidemiologic research. Med Clin (Barc). 2012; 138: 617–621(in Spanish).
24. Ramos R, Balló E, Marrugat J, et al. Validez del Sistema de Información para el Desarrollo de la Investigación en Atención Primaria (SIDIAP) para la investigación en enfermedades vasculares: Estudio EMMA. Rev Esp Cardiol. 2012; 65: 29–37(in Spanish).
25. García-Gil M, Hermosilla E, Prieto-Alhambra D, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Informatics in Primary Care. 2011; 19: 135–145.
26. Mata M, Cos FX, Morros R, et al. Abordatge de la diabetes mellitus tipus 2. Guies de Pràctica Clínica. 2009. Available at: http://www.gencat.cat/ics/professionals/guies/docs/guia_diabetis.pdf, accessed 23 November 2013.
27. Benito P, García R, Puig M, et al. Pathological characteristics of patients with diabetes mellitus type 2, in Spanish primary care. Rev Clin Esp. 2004; 204: 18–24 (in Spanish).
28. Arroyo J, Badía X, de la Calle H, et al. Management of type 2 diabetic patients in primary care in Spain. Med Clin (Barc). 2005; 125: 166–172(in Spanish).
29. Orozco D, Gil VF, Quirce F, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007; 61: 909–915.
30. Mata-Cases M, Roura-Olmeda P, Berengué-Iglesias M, et al. Fifteen years of continuous improvement of quality care of type 2 diabetes mellitus in primary care in Catalonia, Spain. Int J Clin Pract. 2012; 66: 289–298.
31. de la Calle H, Costa A, Díez-Espino J, Franch J, Goday A. Evaluation on the compliance of the metabolic control aims in outpatients with type 2 diabetes mellitus in Spain. The TranSTAR study. Med Clin (Barc). 2003; 120: 446–450 (in Spanish).
32. Liebl A, Mata M, Eschwège E. CODE-2 Advisory Board. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia. 2002; 45(Suppl.): S23–S28.
33. Mita T, Katakami N, Shiraiwa T, et al. Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: The Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). Diabetology & Metabolic Syndrome. 2014; 6: 35.
34. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet. 1999; 353: 617–622.
35. Mengual L, Roura P, Serra M, Montasell M, Prieto G, Bonet S. Multifactorial control and treatment intensity of type 2 diabetes in primary care setting in Catalonia. Cardiovasc Diabetol. 2010; 9: 14.
36. Grupo E. Effectiveness of control of cardiovascular risk factors in type 2 diabetic population of Ciudad Real province. Rev Clin Esp. 2005; 205: 218–222 (in Spanish).
37. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011; 34: 2508–2514.
38. Shaefer C, Reid T, Vlajnic A, Zhou R, DiGenio A. Fasting versus postprandial hyperglucemia as a treatment target to lower elevated A1c. Endocr Pract. 2015; 21: 1323–1332.
39. Shaefer CF, Anderson J. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. Postgrad Med. 2015; 7: 1–8.
40. International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, International Diabetes Federation, 2005.
41. Home P, Riddle M, Cefalu WT, et al. Insulin therapy in people with type 2 diabetes: Opportunities and challenges? Diabetes Care. 2014; 37: 1499–1508.
42. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes: A comprehensive review. Diabetes Technol Ther. 2010; 12: 11–24.
43. Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother. 2010; 44: 1294–1300.
44. Seino Y, Min KW, Niemoeller E. Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012; 14: 910–917.
45. Morales J The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med. 2011; 123: 189–201.
46. Ahrén B. Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World J Diabetes. 2014; 5: 40–51.
47. Nichols GA, Hillier TA, Javor K, Brown JB. Predictors of glycemic control in insulin-using adults with type 2 diabetes. Diabetes Care. 2000; 23: 273–277.
48. Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006; 28: 388–395.
49. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient centered approach. A position statement of the ADA and the EASD. Diabetes Care. 2012; 35: 1364–1379.
50. Qin R, Chen T, Lou Q, Yu D. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. Int J Cardiol. 2013; 167: 342–350.
51. Mata-Cases M, de Prado-Lacueva C, Salido-Valencia V, et al. Incidence of complications and mortality in a type 2 diabetes patient cohort study followed up from diagnosis in a primary healthcare centre. Int J Clin Pract. 2011; 65: 299–307.
52. Arteagoitia JM, Larrañaga MI, Rodríguez JL, Fernandez I, Pinies JA. Incidence, prevalence and coronary Heart disease risk level in know type 2 diabetes: Sentinel practice network study in the Basque Country, Spain. Diabetologia. 2003; 46: 899–909.
53. Phillips LS, Twombly JG. It's time to overcome clinical inertia. Ann Intern Med. 2008; 148: 783–785.
54. Conthe P, Mata M, Orozco D, et al. Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain. Diabetes Res Clin Pract. 2011;91: 108–114.
55. López-Simarro F, Brotons C, Moral I, et al. Inertia and treatment compliance in patients with type 2 diabetes in primary care. Med Clin (Barc). 2012; 138: 377–384 (in Spanish).
56. Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, et al. Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Curr Med Res Opin. 2013; 29: 1495–1502.
57. Cano JF, Franch J Mata M, Grupo de Estudio de la Diabetes en Atención Primaria de Salud (GEDAPS). Guía para el tratamiento de la diabetes tipo 2 en Atención Primaria. Madrid, Ediciones Harcourt SA, 2004.
58. National Institute for Heath and Care Excellence (NICE). NICE guidelines NG28. Type 2 diabetes in adults: management. NICE; 2015. Available at: https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-18373386, accessed 2 January 2016.
59. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013; 19: 327–336.
60. Parchman ML, Wang CP. Initiation of insulin among veterans with type 2 diabetes and sustained elevation of HbA1c. Primary Care Diabetes. 2012; 6: 19–25.
61. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27: 1535–1540.
62. Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control. Diabetes Care. 2005; 28: 600–606.